Skip to content
Human-limitedSystemic copper tripeptide for whole-body rejuvenation

Copper Tripeptide-1 (GHK-Cu Injectable)

Injectable copper peptide for systemic tissue repair.

Overview

Binds to copper-dependent enzymes (lysyl oxidase, superoxide dismutase) and modulates gene expression of over 4,000 genes.

Proposed mechanism

GHK-Cu delivers copper to fibroblasts systemically, activating enzymes required for collagen, elastin, and proteoglycan synthesis while reducing inflammation.

What the evidence supports

Human data exists but the trials are small, short-term, or not yet replicated.

Graded Human-limited

Human data that exists but is thin: open-label work, single-arm studies, small cohorts, or observational follow-up without randomisation.

Key citations

Representative primary sources, including results that did not favour the compound.

  1. [1]

    GHK-Cu systemic effects

    · DOI:10.3390/ijms19071987 · 2018

  2. [2]

    GHK-Cu systemic effects (2018)

    · · 0

Citation records in this build are illustrative placeholders for the design.

Reference information for research purposes. Not medical advice, and not a recommendation to use any compound. Many entries describe substances that are not approved for human use.

Related profiles

Acetyl Tetrapeptide-3 (Darnosine)

Animal

Acetyl tetrapeptide-3 for AGE prevention

Advanced AGE-breaker for deep anti-wrinkle action.

0 RCT · 0 human · 0 preclinical

longevity

AHK-Cu

Human-limited

Copper peptide for skin regeneration and repair

AHK-Cu is a copper-binding tripeptide (Ala-His-Lys) complexed with copper(II) ions, closely related to the well-studied GHK-Cu peptide. It stimulates collagen and glycosaminoglycan synthesis in skin fibroblasts while exerting antioxidant and anti-inflammatory activity. Primarily researched in the context of skin regeneration, wound healing, and hair follicle stimulation.

0 RCT · 0 human · 0 preclinical

skin

Cardiogen

Human-limited

Cardiac peptide bioregulator for heart longevity

Cardiogen is a short synthetic tetrapeptide (Ala-Glu-Asp-Arg) originally developed by the St. Petersburg Institute of Bioregulation and Gerontology in Russia, designed to support cardiac tissue health and function. It acts as a cytoprotective bioregulator targeting cardiomyocytes, promoting cellular repair and reducing age-related deterioration in heart muscle tissue. Research, primarily from Russian preclinical and limited clinical studies, suggests it may help maintain cardiac contractility, reduce fibrosis, and support overall cardiovascular resilience.

0 RCT · 0 human · 0 preclinical

Cardiovascular